Analysis of the Binary Littermate Data in the One‐Way Layout

Lee, Sunho

doi:10.1002/bimj.200390005

Biometrical J

2003

DOI: 10.1002/bimj.200390005

|View full text |Cite

Analysis of the Binary Littermate Data in the One‐Way Layout

Sunho Lee

Abstract: SummaryIn certain experiments with laboratory animals like rodents, it is common to observe the binary littermate data that the fetuses in the same litter provide a set of independent Bernoulli responses conditional on the litter specific abnormal probability. For testing homogeneity of abnormal proportions of several groups, five methods are discussed in the frame of the one-way layout with litter effects. Simulation results show a superiority of the Rao-Scott procedure.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis of highly correlated multiple binary endpoints were discussed in the context of neurotoxocity assays (Han et al, 2004). Lee (2003) described the analysis of binary littermate data like death or the malformation rate for several k-sample tests including the assumption of beta-binomial distribution. The direct inclusion of the assay sensitivity, i.e.…”

mentioning

confidence: 99%

Biostatistics in nonclinical and preclinical drug development

Hothorn

2005

Biom. J.

View full text Add to dashboard Cite

Compared to biostatistics in clinical drug development, much less papers were published in the area of nonclinical and preclinical drug development. There seem to be several reasons for this. First, the "preclinical" and "nonclinical" are contain a wide range of topics. These include, but are not limited to, the candidate drug search process, toxicology and pharmacological studies, drug stability assays, and bioassays. This broad range of subjects causes the definition of this area of statistics to be much vaguer than that for the phase I-IV clinical trials in drug development. Second, due to the interest of the regulators, most notably in the clinical area, the statistical approaches tend to be more standardized. Refer, for example, the detailed description on baseline adjustments in the "CPMP points-toconsider" by Grouin and Lewis (2004). In the nonclinical area only a few statistics-related guidance documents can be found, for example for carcinogenicity studies in toxicology (anonymous, 2001). The number of staff in statistics dedicated to the respective areas was described as directly related to the number of guidelines (Lendrem, 2002). Thus, as a third effect, clinical topics are dominating at international biostatistics conferences. Fourth, in the clinical area is an external pressure for objectivity and correctness, and therefore eventually for statistical presence; because a mistaken decision in nonclinical research does mainly harm the pharmaceutical company, whereas a mistaken decision in clinical development may harm the public primarily.On April [22][23] 2004, the 4th International DIA workshop on statistical methodology in nonclinical research and development took place in Dublin, Ireland. A total of 20 presentations were given in five sessions: statistics for genomics, in vitro pharmacology, statistics for QSAR, advanced modeling in pharmacology, and statistics of quantitative assays. In this special issue of Biometrical Journal, two of the contributions are printed, together with two additional papers on this topic. Straetmans et al. Design and Analysis of Drug Combination ExperimentsA parametric log-logistic Hill-type model for claiming synergy by calculation the confidence intervals of the interaction indices in the ray design (fixed ratios) is discussed. For in vitro assays on microtiter plates a bias correction for plate-location effects is included. The analysis of developmental toxicity studies is performed by random effects threshold doseresponse model for clustered binary-response data with the assumption of an additional hormetic effect to the threshold effect. A score tests derived from a random effects hormetic-threshold dose-response model was compared with the likelihood ratio test in a simulation study. For experimental in vivo data on DEHP evidence for a hormetic effect was concluded, which was not be as strong as the threshold effect. Further to these papers, I would like to discuss the recent development of statistics in the respective areas.Many approaches for the search of poten...

show abstract

mentioning

confidence: 99%

Biostatistics in nonclinical and preclinical drug development

Hothorn

2005

Biom. J.

View full text Add to dashboard Cite

show abstract

Validation of Statistical Methods to Compare Cancellation Rates on the Day of Surgery

Dexter

Marcon

Epstein

et al. 2005

Anesthesia & Analgesia

118

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Analysis of the Binary Littermate Data in the One‐Way Layout

Cited by 2 publications

References 12 publications

Biostatistics in nonclinical and preclinical drug development

Biostatistics in nonclinical and preclinical drug development

Validation of Statistical Methods to Compare Cancellation Rates on the Day of Surgery

Contact Info

Product

Resources

About